Florida Senate - 2023                                     SB 736
       
       
        
       By Senator Brodeur
       
       
       
       
       
       10-00876-23                                            2023736__
    1                        A bill to be entitled                      
    2         An act relating to controlled substances; amending s.
    3         893.03, F.S.; adding nitazene derivatives to the list
    4         of Schedule I controlled substances; providing an
    5         effective date.
    6          
    7  Be It Enacted by the Legislature of the State of Florida:
    8  
    9         Section 1. Paragraph (a) of subsection (1) of section
   10  893.03, Florida Statutes, is amended to read:
   11         893.03 Standards and schedules.—The substances enumerated
   12  in this section are controlled by this chapter. The controlled
   13  substances listed or to be listed in Schedules I, II, III, IV,
   14  and V are included by whatever official, common, usual,
   15  chemical, trade name, or class designated. The provisions of
   16  this section shall not be construed to include within any of the
   17  schedules contained in this section any excluded drugs listed
   18  within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
   19  Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
   20  Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
   21  Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
   22  Anabolic Steroid Products.”
   23         (1) SCHEDULE I.—A substance in Schedule I has a high
   24  potential for abuse and has no currently accepted medical use in
   25  treatment in the United States and in its use under medical
   26  supervision does not meet accepted safety standards. The
   27  following substances are controlled in Schedule I:
   28         (a) Unless specifically excepted or unless listed in
   29  another schedule, any of the following substances, including
   30  their isomers, esters, ethers, salts, and salts of isomers,
   31  esters, and ethers, whenever the existence of such isomers,
   32  esters, ethers, and salts is possible within the specific
   33  chemical designation:
   34         1. Acetyl-alpha-methylfentanyl.
   35         2. Acetylmethadol.
   36         3. Allylprodine.
   37         4. Alphacetylmethadol (except levo-alphacetylmethadol, also
   38  known as levo-alpha-acetylmethadol, levomethadyl acetate, or
   39  LAAM).
   40         5. Alphamethadol.
   41         6. Alpha-methylfentanyl (N-[1-(alpha-methyl-betaphenyl)
   42  ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4
   43  (N-propanilido) piperidine).
   44         7. Alpha-methylthiofentanyl.
   45         8. Alphameprodine.
   46         9. Benzethidine.
   47         10. Benzylfentanyl.
   48         11. Betacetylmethadol.
   49         12. Beta-hydroxyfentanyl.
   50         13. Beta-hydroxy-3-methylfentanyl.
   51         14. Betameprodine.
   52         15. Betamethadol.
   53         16. Betaprodine.
   54         17. Clonitazene.
   55         18. Dextromoramide.
   56         19. Diampromide.
   57         20. Diethylthiambutene.
   58         21. Difenoxin.
   59         22. Dimenoxadol.
   60         23. Dimepheptanol.
   61         24. Dimethylthiambutene.
   62         25. Dioxaphetyl butyrate.
   63         26. Dipipanone.
   64         27. Ethylmethylthiambutene.
   65         28. Etonitazene.
   66         29. Etoxeridine.
   67         30. Flunitrazepam.
   68         31. Furethidine.
   69         32. Hydroxypethidine.
   70         33. Ketobemidone.
   71         34. Levomoramide.
   72         35. Levophenacylmorphan.
   73         36. Desmethylprodine (1-Methyl-4-Phenyl-4
   74  Propionoxypiperidine).
   75         37. 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4
   76  piperidyl]-N-phenylpropanamide).
   77         38. 3-Methylthiofentanyl.
   78         39. Morpheridine.
   79         40. Noracymethadol.
   80         41. Norlevorphanol.
   81         42. Normethadone.
   82         43. Norpipanone.
   83         44. Para-Fluorofentanyl.
   84         45. Phenadoxone.
   85         46. Phenampromide.
   86         47. Phenomorphan.
   87         48. Phenoperidine.
   88         49. PEPAP (1-(2-Phenylethyl)-4-Phenyl-4
   89  Acetyloxypiperidine).
   90         50. Piritramide.
   91         51. Proheptazine.
   92         52. Properidine.
   93         53. Propiram.
   94         54. Racemoramide.
   95         55. Thenylfentanyl.
   96         56. Thiofentanyl.
   97         57. Tilidine.
   98         58. Trimeperidine.
   99         59. Acetylfentanyl.
  100         60. Butyrylfentanyl.
  101         61. Beta-Hydroxythiofentanyl.
  102         62. Fentanyl derivatives. Unless specifically excepted,
  103  listed in another schedule, or contained within a pharmaceutical
  104  product approved by the United States Food and Drug
  105  Administration, any material, compound, mixture, or preparation,
  106  including its salts, isomers, esters, or ethers, and salts of
  107  isomers, esters, or ethers, whenever the existence of such salts
  108  is possible within any of the following specific chemical
  109  designations containing a 4-anilidopiperidine structure:
  110         a. With or without substitution at the carbonyl of the
  111  aniline moiety with alkyl, alkenyl, carboalkoxy, cycloalkyl,
  112  methoxyalkyl, cyanoalkyl, or aryl groups, or furanyl,
  113  dihydrofuranyl, benzyl moiety, or rings containing heteroatoms
  114  sulfur, oxygen, or nitrogen;
  115         b. With or without substitution at the piperidine amino
  116  moiety with a phenethyl, benzyl, alkylaryl (including
  117  heteroaromatics), alkyltetrazolyl ring, or an alkyl or
  118  carbomethoxy group, whether or not further substituted in the
  119  ring or group;
  120         c. With or without substitution or addition to the
  121  piperdine ring to any extent with one or more methyl,
  122  carbomethoxy, methoxy, methoxymethyl, aryl, allyl, or ester
  123  groups;
  124         d. With or without substitution of one or more hydrogen
  125  atoms for halogens, or methyl, alkyl, or methoxy groups, in the
  126  aromatic ring of the anilide moiety;
  127         e. With or without substitution at the alpha or beta
  128  position of the piperidine ring with alkyl, hydroxyl, or methoxy
  129  groups;
  130         f. With or without substitution of the benzene ring of the
  131  anilide moiety for an aromatic heterocycle; and
  132         g. With or without substitution of the piperidine ring for
  133  a pyrrolidine ring, perhydroazepine ring, or azepine ring;
  134  
  135  excluding, Alfentanil, Carfentanil, Fentanyl, and Sufentanil;
  136  including, but not limited to:
  137         (I) Acetyl-alpha-methylfentanyl.
  138         (II) Alpha-methylfentanyl (N-[1-(alpha-methyl-betaphenyl)
  139  ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4
  140  (N-propanilido) piperidine).
  141         (III) Alpha-methylthiofentanyl.
  142         (IV) Benzylfentanyl.
  143         (V) Beta-hydroxyfentanyl.
  144         (VI) Beta-hydroxy-3-methylfentanyl.
  145         (VII) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4
  146  piperidyl]-N-phenylpropanamide).
  147         (VIII) 3-Methylthiofentanyl.
  148         (IX) Para-Fluorofentanyl.
  149         (X) Thenylfentanyl or Thienyl fentanyl.
  150         (XI) Thiofentanyl.
  151         (XII) Acetylfentanyl.
  152         (XIII) Butyrylfentanyl.
  153         (XIV) Beta-Hydroxythiofentanyl.
  154         (XV) Lofentanil.
  155         (XVI) Ocfentanil.
  156         (XVII) Ohmfentanyl.
  157         (XVIII) Benzodioxolefentanyl.
  158         (XIX) Furanyl fentanyl.
  159         (XX) Pentanoyl fentanyl.
  160         (XXI) Cyclopentyl fentanyl.
  161         (XXII) Isobutyryl fentanyl.
  162         (XXIII) Remifentanil.
  163         63.Nitazene derivatives. Unless specifically excepted,
  164  listed in another schedule, or contained within a pharmaceutical
  165  product approved by the United States Food and Drug
  166  Administration, any material, compound, mixture, or preparation,
  167  including its salts, isomers, esters, or ethers, and salts of
  168  isomers, esters, or ethers, whenever the existence of such salts
  169  is possible within any of the following specific chemical
  170  designations containing a benzimidazole ring with an ethylamine
  171  substitution at the 1-position and a benzyl ring substitution at
  172  the 2-position structure:
  173         a. With or without substitution on the benzimidazole ring
  174  with alkyl, alkoxy, carboalkoxy, amino, nitro, or aryl groups,
  175  or halogens;
  176         b. With or without substitution at the ethylamine amino
  177  moiety with alkyl, dialkyl, acetyl, or benzyl groups, whether or
  178  not further substituted in the ring system;
  179         c. With or without inclusion of the ethylamine amino moiety
  180  in a cyclic structure;
  181         d. With or without substitution of the benzyl ring; or
  182         e. With or without replacement of the benzyl ring with an
  183  aromatic ring, including, but not limited to:
  184         (I) Butonitazene.
  185         (II) Clonitazene.
  186         (III) Etodesnitazene.
  187         (IV) Etonitazene.
  188         (V) Flunitazene.
  189         (VI) Isotodesnitazene.
  190         (VII) Isotonitazene.
  191         (VIII) Metodesnitazene.
  192         (IX) Metonitazene.
  193         (X) Nitazene.
  194         (XI) N-Desethyl Etonitazene.
  195         (XII) N-Desethyl Isotonitazene.
  196         (XIII) N-Piperidino Etonitazene.
  197         (XIV) N-Pyrrolidino Etonitazene.
  198         (XV) Protonitazene.
  199         Section 2. This act shall take effect July 1, 2023.